Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 128, 2008 - Issue 4
Submit an article Journal homepage
149
Views
25
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer

Heikki Luukkaa Department of Otorhinolaryngology-Head and Neck Surgery, University of Turku, Turku, Finland
,
Pekka Klemi Department of Pathology, University of Turku, Turku, Finland
,
Pirkko Hirsimäki Department of Pathology, Turku University Central Hospital, Turku, Finland
,
Tero Vahlberg Department of Biostatistics, University of Turku, Turku, Finland
,
Atte Kivisaari Department of Dermatology, University of Turku, Turku, Finland; Medicity Research Laboratory, University of Turku, Turku, Finland
,
Veli-Matti Kähäri Department of Dermatology, University of Turku, Turku, Finland; Medicity Research Laboratory, University of Turku, Turku, Finland
&
Reidar Grénman Department of Otorhinolaryngology-Head and Neck Surgery, University of Turku, Turku, Finland; Department of Medical Biochemistry and Molecular Biology, University of Turku, Turku, FinlandCorrespondence[email protected]
 show all
Pages 482-490 | Received 22 Oct 2007, Published online: 08 Jul 2009

References

  • Vander Poorten VL. Salivary gland carcinoma – stepping up the prognostic ladder. University of Amsterdam, Amsterdam 2002
  • Finnish Cancer Registry, 15 August 2007. Available from URL: http://www.cancerregistry.fi/eng/statistics/.
  • Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, et al. Salivary gland cancer in Finland 1991–96: an evaluation of 237 cases. Acta Otolaryngol (Stockh) 2005; 125: 207–14
  • Eveson JW. Troublesome tumours 2: borderline tumours of salivary glands. J Clin Pathol 1992; 45: 369–77
  • De S, Fenton JE, Jones AS. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. J Laryngol Otol 2005; 119: 436–42
  • Nagase H, Woessner JF, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–4
  • Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827–39
  • Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie 2005; 87: 273–86
  • Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005; 5: 203–20
  • Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 5158–66
  • Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002; 97: 432–8
  • Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996; 2: 461–2
  • Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998; 185: 256–61
  • Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998; 43: 791–7
  • Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999; 12: 669–74
  • Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999; 154: 469–80
  • Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997; 151: 499–508
  • Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006; 28: 225–34
  • Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000; 17: 1099–105
  • Azuma M, Tamatani T, Fukui K, Yoshida H, Kamogashira T, Ogino K, et al. Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. Int J Cancer 1993; 54: 669–76
  • Soini Y, Autio-Harmainen H. Synthesis and degradation of basement membranes in benign and malignant salivary gland tumours. A study by in situ hybridization. J Pathol 1993; 170: 291–6
  • Freitas VM, Scheremeta B, Hoffman MP, Jaeger RG. Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. Oral Oncol 2004; 40: 483–9
  • Kayano K, Shimada T, Shinomiya T, Nakai S, Hisa Y, Aoki T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol 2004; 202: 403–11
  • Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004; 44: 222–31
  • Westernoff TH, Jordan RC, Regezi JA, Ramos DM, Schmidt BL. Beta-6 Integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol 2005; 41: 170–4
  • O-Charoenrat P, Rhys-Evans P, Eccles S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer 2002; 100: 527–33

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.